CArdioMetabolism and Atherosclerotic PlaqUe progreSsion
Recruiting · NCT05117424 · Observational (researchers observe without assigning treatment) · Lead sponsor: Ruijin Hospital
View the official record on ClinicalTrials.gov →What this trial is about
Systematic metabolic diseases are closely related to prevalence and progression of atherosclerosis. This prospective cohort consecutively enrolls patients with coronary artery disease compliacted with metabolic abnormalities such as diabtetes, prediabetes, obesity, chronic kidney disease and hyperuricemia.
Who can take part
Age range
18 Years to 80 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Age 18-80 years
- Established coronary artery disease or metabolic disorders, including:
- Type 2 diabetes diagnosed by one of the following criteria:
- HbA1c \>/= 6.5% Fasting plasma glucose \>/= 7.0 mmol/l (confirmed) 2h plasma glucose value during OGTT \>/= 11.1 mmol/l Already receiving glucose-lowering agents
- Prediabetes
- Obesity
- Chronic kidney disease
- Hyperuricemia
- Dyslipidemia
Exclusion criteria
- Severe liver failure (Child-Pugh grade B to C)
- Severe anemia (hemoglobin \< 60g/L)
- Familial hypercholesterolemia
- Active malignant tumor
- Active autoimmune diseases on corticosteroids
- Acute or chronic infection
- Life expectancy \< 1 year
Where it is running
2 locations listed.
- Ruijin Hospital, Shanghai Jiaotong University School of Medicine - Shanghai, China
- Ruijin Hospital, Shanghai Jiaotong University School of Medicine - Shanghai, China